Drug research

Pamrevlumab

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as FG-3019; Monoclonal Antibody to Connective tissue growth factor (CTGF), FG-3019

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)NCT02606136	Kyntra Bio	Phase 2	Terminated	2020-05-07Actual
Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)NCT04371666	Kyntra Bio	Phase 3	Terminated	2023-02-13Actual
Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMDNCT04632940	Kyntra Bio	Phase 3	Terminated	2023-06-12Actual
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)NCT04419558	Kyntra Bio	Phase 3	Terminated	2023-09-04Actual
Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)NCT03955146	Kyntra Bio	Phase 3	Terminated	2023-03-20Actual

Kyntra BioTerminatedPrimary completion: 2020-05-07 · Actual

Trial details

Kyntra BioTerminatedPrimary completion: 2023-02-13 · Actual

Trial details

Kyntra BioTerminatedPrimary completion: 2023-06-12 · Actual

Trial details

Kyntra BioTerminatedPrimary completion: 2023-09-04 · Actual

Trial details

Kyntra BioTerminatedPrimary completion: 2023-03-20 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.